| NKG2A blockade potentiates CD8 T cell immunity induced by cancer vaccines N van Montfoort, L Borst, MJ Korrer, M Sluijter, KA Marijt, SJ Santegoets, ... Cell 175 (7), 1744-1755. e15, 2018 | 325 | 2018 |
| Dual inhibition of Ang-2 and VEGF receptors normalizes tumor vasculature and prolongs survival in glioblastoma by altering macrophages TE Peterson, ND Kirkpatrick, Y Huang, CT Farrar, KA Marijt, J Kloepper, ... Proceedings of the National Academy of Sciences 113 (16), 4470-4475, 2016 | 311 | 2016 |
| Glutaminyl cyclase is an enzymatic modifier of the CD47-SIRPα axis and a target for cancer immunotherapy MEW Logtenberg, JHM Jansen, M Raaben, M Toebes, K Franke, ... Nature medicine 25 (4), 612-619, 2019 | 198 | 2019 |
| PD-L1 expression on malignant cells is no prerequisite for checkpoint therapy JW Kleinovink, KA Marijt, MJA Schoonderwoerd, T van Hall, F Ossendorp, ... Oncoimmunology 6 (4), e1294299, 2017 | 162 | 2017 |
| Identification of non-mutated neoantigens presented by TAP-deficient tumors KA Marijt, L Blijleven, EME Verdegaal, MG Kester, DJ Kowalewski, ... Journal of Experimental Medicine 215 (9), 2325-2337, 2018 | 75 | 2018 |
| Metabolic stress in cancer cells induces immune escape through a PI3K-dependent blockade of IFNγ receptor signaling KA Marijt, M Sluijter, L Blijleven, SH Tolmeijer, FA Scheeren, ... Journal for immunotherapy of cancer 7, 1-12, 2019 | 74 | 2019 |
| Glucocorticoid receptor antagonism reverts docetaxel resistance in human prostate cancer J Kroon, M Puhr, JT Buijs, G Van Der Horst, DM Hemmer, KA Marijt, ... Endocrine-related cancer 23 (1), 35-45, 2016 | 69 | 2016 |
| Dendritic cell vaccination and CD40-agonist combination therapy licenses T cell-dependent antitumor immunity in a pancreatic carcinoma murine model SP Lau, N van Montfoort, P Kinderman, M Lukkes, L Klaase, ... Journal for immunotherapy of cancer 8 (2), 2020 | 61 | 2020 |
| Tumor-targeted silencing of the peptide transporter TAP induces potent antitumor immunity G Garrido, B Schrand, A Rabasa, A Levay, F D’Eramo, A Berezhnoy, ... Nature communications 10 (1), 3773, 2019 | 58 | 2019 |
| TEIPP antigens for T-cell based immunotherapy of immune-edited HLA class Ilow cancers KA Marijt, EM Doorduijn, T van Hall Molecular immunology 113, 43-49, 2019 | 48 | 2019 |
| T cells specific for a TAP-independent self-peptide remain naïve in tumor-bearing mice and are fully exploitable for therapy EM Doorduijn, M Sluijter, KA Marijt, BJ Querido, SH van der Burg, ... Oncoimmunology 7 (3), e1382793, 2018 | 26 | 2018 |
| To TAP or not to TAP: alternative peptides for immunotherapy of cancer KA Marijt, T van Hall Current Opinion in Immunology 64, 15-19, 2020 | 18 | 2020 |
| Vaccination against nonmutated neoantigens induced in recurrent and future tumors G Garrido, B Schrand, A Levay, A Rabasa, A Ferrantella, DM Da Silva, ... Cancer immunology research 8 (7), 856-868, 2020 | 12 | 2020 |
| Association of cognitive function with increased risk of cancer death and all-cause mortality: Longitudinal analysis, systematic review, and meta-analysis of prospective … S Rostamian, S le. Cessie, KA Marijt, JW Jukema, SP Mooijaart, ... PLoS One 17 (1), e0261826, 2022 | 11 | 2022 |
| Cross-presentation of a TAP-independent signal peptide induces CD8 T immunity to escaped cancers but necessitates anchor replacement KA Marijt, L Griffioen, L Blijleven, SH van der Burg, T van Hall Cancer Immunology, Immunotherapy 71 (2), 289-300, 2022 | 8 | 2022 |
| TEIPP peptides: exploration of unTAPped cancer antigens KA Marijt, SH Van Der Burg, T van Hall Oncoimmunology, 2019 | 8 | 2019 |
| Abstract LB-346: Dual inhibition of Ang-2 and VEGF receptors normalizes tumor vasculature and prolongs survival in glioblastoma by altering macrophages Z Amoozgar, TE Peterson, ND Kirkpatrick, Y Huang, CT Farrar, KA Marijt, ... Cancer Research 76 (14_Supplement), LB-346-LB-346, 2016 | 2 | 2016 |
| Prorapeutic vaccination against shared antigens induced in future tumors. G Garrido, B Schrand, A Levay, A Rabasa, A Ferrantella, D Da Silva, ... CANCER IMMUNOLOGY RESEARCH 8 (3), 98-99, 2020 | | 2020 |
| Abstract B26: Prorapeutic vaccination against shared antigens induced in future tumors G Garrido, B Schrand, A Levay, A Rabasa, A Ferrantella, D Da Silva, ... Cancer Immunology Research 8 (3_Supplement), B26-B26, 2020 | | 2020 |
| Vaccination against TAP downregulation-induced neoantigens to prevent future tumor development in the setting of recurrence or premalignancy GG Hidalgo, B Schrand, A Rabasa, A Levay, T Gefen, GB Bhuwan, ... CANCER IMMUNOLOGY RESEARCH 7 (2), 2019 | | 2019 |
